Oral budesonide in the treatment of chronic refractory pouchitis;Budesonida oral en el tratamiento de la reservoritis crónica refractaria

Gastroenterologia y Hepatologia

Volumn 31, Issue 8, 2008, Pages 485-489

  Cabriada Nuño, José Luis ^a   Hernández Martín, Anaiansi ^a   Bernal Martínez, Antonio ^a   Zabalza Estévez, Iñaki ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CIPROFLOXACIN; METRONIDAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DIGESTIVE TRACT ENDOSCOPY; DISEASE ACTIVITY; DRUG CAPSULE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; ILEITIS; LABORATORY; MALE; OPEN STUDY; PROSPECTIVE STUDY; REMISSION; SCORING SYSTEM; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 59949104665     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13127089     Document Type: Article

References (28)

1. Gionchetti P, Rizzello F, Campieri M. Reservoritis. En: Gassull MA, Gomollón F, Hinojosa J, Obrador A, editores. Enfermedad inflamatoria intestinal. Madrid: Arán; 2007. p. 311-8.
2. Penna C, Dozois R, Tremaine W, Sandborn W, LaRusso N, Schleck C, et al. Pouchitis alter ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frecuency in patients with associated primary sclerosing cholangitis. Gut. 1996;38:1012-8.
3. Shen B, Fazio V, Remzi F, Lashner B. Clinical approach to diseases of ileal pouch-anal anastomosis. Am J Gastroenterol. 2005;100:2796-807.
4. Mahadevan U, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology. 2003;124:1636-50.
5. Pardi DS, Sandborn WJ. Systematic review: the management of pouchitis. Aliment Pharmacol Ther. 2006;23:1087-96.
6. Shen B, Achkar JP, Connor JT, Ormsby A, Remzi F, Bevins C, et al. Modified pouchitis disease activity index:a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum. 2003;46:748-53.
7. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis alter ileal pouch-anal anastomosis: a pouchitis disease activity index. Mayo Clin Proc. 1994;69:409-15.
8. Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study of the incidence, timing,and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg. 1996;131:497-502.
9. Gionchetti P, Rizzello F, Ventura A, Ugolini F, Rossi M, Brigidi P, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther. 1999;13:713-8.
10. Abdelrazeq AS, Kandiyil N, Botterill D, Lund JN, Reynolds JR, Holdsworth PJ, et al. Predictors for acute and chronic pouchitis following restorative proctocolectomy for ulcerative colitis. Colorectal Dis. En prensa 2007.
11. Gosselink MP, Schouten WR, Van Lieshout LM, Hop WC, Laman JD, Ruseler-Van Embden JG. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum. 2004;47:1519-25.
12. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci. 1994;39:1193-6.
13. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis. 2001;7:301-5.
14. Mimura T, Rizzello F, Helwing U, Poggioli G, Schreiber S, Talbot IC, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther. 2002;16:909-17.
15. Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis. 2005;7:182-6.
16. Sandborn W, McLeod R, Jewell D. Pharmacotherapy for induction and maintenance of remission in pouchitis. The Cochrane Database of Systematic Reviews. Cochrane Library. Issue1. Oxford: Update Software; 2003.
17. Welters CF, Heineman E, Thunnissen FB, Van den Bogaard AE, Soeters PB, Baeten CG. Effect of dietary inulin supple-mentation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum. 2002;45:621-7.
18. Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther. 2004;19:281-6.
19. Patel RT, Bain I, Youngs D, Keighley MR. Cytokine production in pouchitis is similar to that in ulcerative colitis. Dis Colon Rectum. 1995;38:831-7.
20. Gertner DJ, Rampton DS, Madden MV, Talbot IC, Nicholls RJ, Lennard-Jones JE. Increased leukotriene B4 release from ileal pouch mucosa in ulcerative colitis compared with familial adenomatous polyposis. Gut. 1994;35:1429-32.
21. Sambuelli A, Boerr L, Negreira S, Gil A, Camartino G, Huernos S, et al. Budesonide enema in pouchitis-a double blind, double-dummy, controlled trial. Aliment Pharmacol Ther. 2002;16:27-34.
22. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thompson AB, Williams CN, et al. Oral budesonide for active Crohn's disease. N Engl J Med. 1994;331:836-41.
23. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994;331:842-5.
24. Estudio Prospectivo Delphi. Costes sociales y económicos de la enfermedad inflamatoria intestinal (EII). Sintomatología básica y calidad de vida: 92-111.
25. Gionchetti P, Rizzello F, Poggioli G, Pierangeli F, Laureti S, Morselli C, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther. 2007;25:1231-6.
26. Chopra A, Pardi D, Loftus E, Tremaine WJ, Egan L, Faubion W, et al. Budesonide in the treatment of inflammatory bowel disease:the first year of experience in clinical practice. Inflamm Bowel Dis. 2006;12:29-32.
27. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-9.
28. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-11.